These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 8471331)

  • 21. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.
    Escudier B; Farace F; Angevin E; Charpentier F; Nitenberg G; Triebel F; Hercend T
    Eur J Cancer; 1994; 30A(8):1078-83. PubMed ID: 7654433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive regimen of cytokines with interleukin-2 and interferon alfa-2b in selected patients with metastatic renal carcinoma.
    Négrier S; Mercatello A; Bret M; Merrouche Y; Coronel B; Favrot M; Gaspard M; Dorez D; Philip I; Lanier F
    J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):62-8. PubMed ID: 7728307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cytokine therapy of metastatic renal cell carcinoma].
    Otto T; Goepel M; Luboldt HJ; Rübben H
    Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of interferon in renal cell carcinoma.
    Muss HB
    Eur J Cancer; 1991; 27 Suppl 4():S84-7. PubMed ID: 1724728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma.
    Escudier B; Farace F; Angevin E; Triebel F; Antoun S; Leclercq B; Brandely M; Aboudaram A; Nitenberg G; Hercend T
    Eur J Cancer; 1993; 29A(5):724-8. PubMed ID: 8471331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interferon-alpha therapy in hypernephroma].
    Sagaster KP
    Wien Med Wochenschr; 1993; 143(16-17):443-7. PubMed ID: 8273370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP; Whitehead RP; Ward DL; Hemstreet GP; Bradley EC
    J Urol; 1993 Sep; 150(3):814-20. PubMed ID: 8345590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

  • 29. Medical treatment of advanced renal cell carcinoma: present options and future directions.
    Canobbio L; Miglietta L; Boccardo F
    Cancer Treat Rev; 1996 Mar; 22(2):85-104. PubMed ID: 8665566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.